Live Breaking News & Updates on Raquel Cona|Page 4

Stay updated with breaking news from Raquel cona. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy ; On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to. | May 11, 2023 ....

San Diego , United States , Joyce Allaire , Linda Marb , Raquel Cona , Exosome Platform Technology , Capricor Therapeutics Inc , Nippon Shinyaku Co Ltd , World Vaccine Congress , Globenewswire Inc , Capricor Company Contact , Clinical Research Forum , Duchenne Muscular Dystrophy Program , Exchange Commission , Lifesci Advisors , Strategic Communications , Top Ten Clinical Research Achievement Award , Enrollment Continues , Duchenne Muscular Dystrophy , Report Interim Analysis , Fourth Quarter , Label Extension Data , Second Quarter , Webcast Today , Recent Operational , Muscular Dystrophy Program ,

Capricor Therapeutics Presents at 2023 Muscular Dystrophy

Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients. ....

United States , Linda Marb , Joyce Allaire , Craig Mcdonald , Raquel Cona , Exchange Commission On , Muscular Dystrophy Association , Department Of Physical Medicine , Capricor Company Contact , Strategic Communications , Capricor Therapeutics Inc , University Of California , Lifesci Advisors , Scientific Conference , Principal Investigator , Physical Medicine , Rehabilitation Chair , Upper Limb , Label Extension , Duchenne Muscular Dystrophy , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Investigational New Drug , Media Contact , Investor Contact ,

Capricor Therapeutics and Nippon Shinyaku Enter Partnership

-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise- . ....

United States , Linda Marb , Toru Nakai , Joyce Allaire , Raquel Cona , Nippon Shinyaku Co Ltd , Lifesci Advisors , Exchange Commission On , Corporate Communications Dept , Strategic Communications , Capricor Therapeutics Inc , Capricor Company Contact , Expands Partnership , Nippon Shinyaku , Leverage Deep Experience , Drug Development , Rare Diseases , Upfront Payment , Additional Potential Milestone , Meaningful Double Digit Percentage , Revenue Based , Distribution Agreement , Upper Limb , Marketing Authorization , Duchenne Muscular , Private Securities Litigation Reform Act ,

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

19.01.2023 - -Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 . ....

Joyce Allaire , Raquel Cona , Lifesci Advisors , Exchange Commission On , Capricor Therapeutics Inc , Strategic Communications , Parent Project Muscular Dystrophy , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Quarterly Report , Investigational New Drug , Media Contact , Investor Contact , Sci Advisors ,

Capricor Announces Publication Highlighting New Advances

-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE. ....

Joyce Allaire , Linda Marban , Raquel Cona , Lifesci Advisors , Exchange Commission On , Strategic Communications , Capricor Therapeutics Inc , Capricor Company Contact , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Quarterly Report , Investigational New Drug , Media Contact , Investor Contact , Sci Advisors , Company Contact , Chief Financial , Nasdaq Capr , Capricor Therapeutics ,